Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NSPR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsInspireMD launches up to $75M at-the-market stock offering, replaces prior Piper Sandler program
Filed April 3, 2026 · Period ending April 3, 2026 · ~1 min read
Key Changes
-
high
Company established new ATM offering to sell up to $75M of common stock through BTIG at market prices, giving management flexibility to raise capital when needed. BTIG receives 3% commission on sales.
Item 1.01 verify on EDGAR → -
medium
Terminated previous up to $75M ATM agreement with Piper Sandler after selling 1.36M shares under that program. No termination penalties apply.
Item 1.01 verify on EDGAR → -
medium
Proceeds will fund general operations including R&D, sales and marketing, and working capital. Broad language gives management discretion over capital deployment.
Item 1.01 verify on EDGAR →
Summary
InspireMD has replaced its existing at-the-market equity offering program with a new up to $75 million facility. The company terminated its agreement with Piper Sandler (under which it had sold 1.36 million shares) and immediately entered into a fresh ATM arrangement with BTIG on the same day.
This swap suggests the company is maintaining its ability to raise capital opportunistically by selling shares into the market at prevailing prices, rather than through traditional block offerings. For retail shareholders, this means potential dilution of up to $75 million worth of shares, though the timing and amount are at management's discretion.
ATM offerings allow companies to raise smaller amounts of capital when stock prices are favorable, but they also create ongoing dilution uncertainty. The 3% commission to BTIG is standard for these arrangements. Investors should monitor the company's quarterly filings to track how many shares are actually sold under this new program and at what prices, as this will determine the real dilutive impact on existing shareholders.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
BTIG is entitled to a commission of up to 3.0% of the gross proceeds from the Shares sold under the Equity Distribution Agreement.
The sales agent will receive up to 3% of gross proceeds as compensation for selling shares under this agreement. This is a standard commission rate for ATM offerings and will reduce the net proceeds the company receives from any stock sales.
Added in current filing · verify on EDGAR →
The Company currently intends to use any net proceeds from the Offering for its operations, including, but not limited to, research and development, sales and marketing, and working capital and other general corporate purposes, and any other purposes that may be stated in any future prospectus supplement.
Proceeds from any stock sales will be used for general corporate purposes including research and development, sales and marketing, and working capital. This is broad language giving management flexibility in how to deploy the capital raised.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Effective as of April 3, 2026, the Company terminated (i) the Piper EDA and (ii) the prospectus related to the Prior ATM Offering.
InspireMD terminated its equity distribution agreement with Piper Sandler that allowed the company to sell up to $75 million of shares in an at-the-market offering. The termination is effective April 3, 2026, and the company will no longer offer or sell shares under this program.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company is not subject to any termination penalties related to the termination of the Piper EDA.
InspireMD confirmed there are no financial penalties or costs associated with terminating the equity distribution agreement early. This is a clean exit from the ATM offering arrangement.
Event · Item 9.01 — Financial Statements and Exhibits
InspireMD entered into an at-the-market equity distribution agreement with BTIG to sell shares, effective April 3, 2026.
Added in current filing · verify on EDGAR →
Equity Distribution Agreement by and between InspireMD, Inc. and BTIG, LLC, dated April 3, 2026
InspireMD has entered into an Equity Distribution Agreement with BTIG, LLC, a broker-dealer, dated April 3, 2026. This type of agreement typically allows the company to sell shares of its common stock from time to time in at-the-market offerings, providing a mechanism for raising capital as needed. The filing includes a legal opinion from Greenberg Traurig regarding the validity of the shares to be issued under this arrangement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify